December 1, 2022 C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmac
C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias TUCSON, Ariz., November 15, 2022 — The Critical Path for Alzheimer’s Disease (CPAD) at the Critical Path Institute (C-Path) an
C-Path and EFACTS Announce Data Sharing Agreement Making RDCA-DAP the Largest Worldwide Database for Friedreich’s Ataxia TUCSON, Ariz., Nov. 10, 2022 — Critical Path Institute (C-Path) and the European Friedreich’s Ataxia Consortium for Translatio
November 2, 2022 C-Path and Eisai Data Sharing Collaboration to Include Lennox-Gastaut Syndrome Registry and Clinical Trial Data TUCSON, Ariz., Nov. 2, 2022 — Critical Path Institute (C-Path) and the Eisai Co., Ltd. (Eisai) today announced a joint collabora
FDA Expands Support of C-Path CDRC to Automate EHR Data Extraction Emory, Johns Hopkins Medicine, Infectious Disease Data Observatory/Oxford, Society of Critical Care Medicine and May
C-Path Appoints Neuropharmacology Expert as New Vice President – Rare and Orphan Disease Programs Dr. Collin Hovinga will lead two public-private partnerships at C-Path — the Rare Disease Cures Accelerator Data and Analytics P
C-Path’s Ramona Walls Promoted to Executive Director of Data Science TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) has named Ramona L. Walls, Ph.D., as Executive Director of Da
C-Path and Sturge-Weber Foundation Announce Data Sharing Agreement to Support Treatment Development for Sturge-Weber Syndrome TUCSON, Ariz., October 20, 2022 — Critical Path Institute (C-Path) and the Sturge-Weber Foundation today announced a joint colla
C-Path’s Transplant Therapeutics Consortium Receives EMA Draft Qualification Opinion for iBox Scoring System The draft EMA qualification opinion is available for public consultation until November 17, 2022 Secondary endpoint prognostic for
C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Alpha-1 Antitrypsin Deficiency TUCSON, Ariz., Oct. 6, 2022 — Critical Path Institute (C-Path) today announced that it has recently launched a pre-consortium co
